LOGIN  |  REGISTER
Amneal Pharmaceuticals
C4 Therapeutics

Integra LifeSciences to Host Second Quarter 2024 Financial Results Conference Call on July 29, 2024

July 15, 2024 | Last Trade: US$21.80 0.09 0.41

PRINCETON, N.J., July 15, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will release second quarter 2024 financial results on Monday, July 29, 2024, prior to the market open. In conjunction with the earnings release, Integra’s management team will host a conference call at 8:30 a.m. ET.

A live webcast will be available on the Investors section of the Company’s website at investor.integralife.com. For those planning to participate on the call, register here to receive dial-in details and an individual pin. While not required, joining 10 minutes before the event starts is recommended. A webcast replay of the conference call will be available on the Investors section of the Company’s website following the call.

About Integra LifeSciences

At Integra LifeSciences, we are driven by our purpose of restoring patients’ lives. We innovate treatment pathways to advance patient outcomes and set new standards of surgical, neurologic, and regenerative care. We offer a comprehensive portfolio of high quality, leadership medical technology brands. For the latest news and information about Integra and its products, please visit www.integralife.com

Investor Relations:
Chris Ward
(609) 772-7736
This email address is being protected from spambots. You need JavaScript enabled to view it.   

Media Contact:
Laurene Isip
(609) 208-8121
This email address is being protected from spambots. You need JavaScript enabled to view it.

Viking Therapeutics

Stock Quote

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB